Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROSHARES TRUST (ZBIO) Cash from Operations: 2023-2024

Historic Cash from Operations for Zenas BioPharma (ZBIO) over the last 2 years, with Dec 2024 value amounting to -$119.7 million.

  • Zenas BioPharma's Cash from Operations fell 32.41% to -$41.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.5 million, marking a year-over-year decrease of 64.19%. This contributed to the annual value of -$119.7 million for FY2024, which is 292.00% down from last year.
  • Latest data reveals that Zenas BioPharma reported Cash from Operations of -$119.7 million as of FY2024, which was down 292.00% from -$30.5 million recorded in FY2023.
  • In the past 5 years, Zenas BioPharma's Cash from Operations ranged from a high of -$30.5 million in FY2023 and a low of -$119.7 million during FY2024.
  • Its 2-year average for Cash from Operations is -$75.1 million, with a median of -$75.1 million in 2023.
  • Data for Zenas BioPharma's Cash from Operations shows a maximum YoY slumped of 292.00% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Zenas BioPharma's Cash from Operations stood at -$30.5 million in 2023, then crashed by 292.00% to -$119.7 million in 2024.